First European participant recruited to asthma study at the NIHR Patient Recruitment Centre Bradford
A patient in Yorkshire and Humber is the first to be recruited in Europe to a new study investigating the safety of an injection for adults with asthma.
The study — supported locally by the NIHR Clinical Research Network Yorkshire and Humber — welcomed its first Europe participant at the NIHR Patient Recruitment Centre in Bradford.
The study aims to evaluate the efficacy, safety and tolerability of an investigational drug (amlitelimab), developed by Sanofi for the treatment of immune-mediated diseases such as, atopic dermatitis and asthma.
Researchers are looking for individuals between the ages of 18-75 who have moderate to severe asthma to take part. The study will include approximately 420 participants across 15 countries.
Karen Regan, Lead Clinical Research Nurse and Business Manager (Clinical) at the PRC Bradford said:
“PRC Bradford were delighted with this achievement, it's like scoring a world cup goal. The best part of it though, is it means more of our patients are getting an early opportunity to take part in a clinical trial and the associated benefits this provides.”
Being the first country to recruit a patient in a global trial is a key performance indicator for the life sciences industry as it shows that the UK can support the rapid set-up and recruitment of studies.
For more information on the NIHR Patient Recruitment Centre in Bradford, visit https://local.nihr.ac.uk/prc/bradford/